Anzeige
Anzeige

Archive

Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Obesity and vascular disease

DOI: https://doi.org/10.1160/TH13-02-0132
Issue: 2013: 110/4 (Oct) pp. 623-856
Pages: 834-843

Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism

R. Lecumberri (1), A. Alfonso (1), D. Jiménez (2), C. Fernández Capitán (3), P. Prandoni (4), P. S. Wells (5), G. Vidal (6), G. Barillari (7), M. Monreal (8), and the RIETE investigators

(1) Hematology Service, Clínica Universidad de Navarra, Pamplona, Spain; (2) Department of Pneumonology, Hospital Universitario Ramón y Cajal, Madrid, Spain; (3) Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain; (4) Department of Cardiothoracic and Vascular Sciences, University of Padua, Padua, Italy; (5) Chief and Chair Department of Medicine, University of Ottawa, Ottawa Hospital, General Campus, Ottawa Ontario, Canada; (6) Department of Internal Medicine, Corporació Sanitaria Universitaria Parc Taulí, Sabadell, Barcelona, Spain; (7) Department of Internal Medicine, Center for Hemorrhagic and Thrombotic Disorders, Udine, Italy; (8) Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Badalona, Barcelona, Spain

Keywords

pulmonary embolism, Deep-vein thrombosis, recurrent thromboembolism, major bleeding, case-fatality rate

Summary

In patients with venous thromboembolism (VTE), assessment of the risk of fatal recurrent VTE and fatal bleeding during anticoagulation may help to guide intensity and duration of therapy. We aimed to provide estimates of the case-fatality rate (CFR) of recurrent VTE and major bleeding during anticoagulation in a ‘real life’ population, and to assess these outcomes according to the initial presentation of VTE and its etiology. The study included 41,826 patients with confirmed VTE from the RIETE registry who received different durations of anticoagulation (mean 7.8 ± 0.6 months). During 27,110 patient-years, the CFR was 12.1% (95% CI, 10.2–14.2) for recurrent VTE, and 19.7% (95% CI, 17.4–22.1) for major bleeding. During the first three months of anticoagulant therapy, the CFR of recurrent VTE was 16.1% (95% CI, 13.6–18.9), compared to 2.0% (95% CI, 0–4.2) beyond this period. The CFR of bleeding was 20.2% (95% CI, 17.5–23.1) during the first three months, compared to 18.2% (95% CI, 14.0–23.2) beyond this period. The CFR of recurrent VTE was higher in patients initially presenting with PE (18.5%; 95% CI, 15.3–22.1) than in those with DVT (6.3%; 95% CI, 4.5–8.6), and in patients with provoked VTE (16.3%; 95% CI, 13.6–19.4) than in those with unprovoked VTE (5.5%; 95% CI, 3.5–8.0). In conclusion, the CFR of recurrent VTE decreased over time during anticoagulation, while the CFR of major bleeding remained stable. The CFR of recurrent VTE was higher in patients initially presenting with PE and in those with provoked VTE.

You may also be interested in...

1.
A meta-analysis of randomised controlled trials

F. Dentali (1), N. Mumoli (2), D. Prisco (3), A. Fontanella (4), M. N. D. Di Minno (5)

Thromb Haemost 2017 117 3: 606-617

https://doi.org/10.1160/TH16-08-0595

2.

W. Ageno (1), I. B. Casella (2), C. K. Han (3), G. E. Raskob (4), S. Schellong (5), S. Schulman (6), D. E. Singer (7), K. Kimura (8), W. Tang (9), M. Desch (9), S. Z. Goldhaber (10)

Thromb Haemost 2017 117 2: 415-421

https://doi.org/10.1160/TH16-07-0566

3.

J. Trujillo-Santos (1), P. Di Micco (2), F. Dentali (3), J. Douketis (4), J. A. Díaz-Peromingo (5), M. J. Núñez (6), I. Cañas (7), D. Mastroiacovo (8), M. Saraiva de Sousa (9), M. Monreal (10), RIETE Investigators

Thromb Haemost 2017 117 2: 382-389

https://doi.org/10.1160/TH16-07-0494